FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kassberg Thomas Richard					2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director						
(Last)	(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC.				3. Date of Earliest Transaction (Month/Day/Year) 03/01/2024								X Officer (give title Other (specify below) CBO & EVP						
60 LEVERONI COURT				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Chec Line)														
(Street) NOVATO CA 94949						X Form filed by One Reporting Person Form filed by More than One Reporting Person													
(City)	(S	tate)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication													
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												l to						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
			2. Transaction Date (Month/Day/Year)		ar) I	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ties Acquired (A) or I Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	r Pri	ice	Transact (Instr. 3 a	ion(s)			(Instr. 4)
Common Stock					/01/2024				A		17,800	(1) A		\$ <mark>0</mark>	264	4,660		D	
Common Stock (03/01	01/2024				A		957 ⁽²⁾			\$ <mark>0</mark>	265	5,617		D	
Common Stock				03/01	3/01/2024				F		274(3)	D	\$:	53.69	265,343			D	
Common	Stock			03/01/2024		4			S		1,011	4) D	\$:	53.76	264,332 ⁽⁵⁾		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, Trans			n of		6. Date Exercis Expiration Date (Month/Day/Ye		•	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		rity (B. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date Title Amount or Number of Shares								
Stock Option (Right to Buy)	\$53.69	03/01/2024			A		31,400		(6)		03/01/2034	Common Stock	31,4	400 \$0		31,400		D	

Explanation of Responses:

- 1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- 2. Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
- 3. Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- 4. Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- 5. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- 6. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

/s/ Karah Parschauer, attorneyin-fact

** Signature of Reporting Person

03/05/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.